144 related articles for article (PubMed ID: 32400847)
1. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade.
St-Gelais J; Denavit V; Giguère D
Org Biomol Chem; 2020 May; 18(20):3903-3907. PubMed ID: 32400847
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of interspecies differences in the binding affinity of TD139 to Galectin-3.
Kumar A; Paul M; Panda M; Jayaram S; Kalidindi N; Sale H; Vetrichelvan M; Gupta A; Mathur A; Beno B; Regueiro-Ren A; Cheng D; Ramarao M; Ghosh K
Glycobiology; 2021 Nov; 31(10):1390-1400. PubMed ID: 34228782
[TBL] [Abstract][Full Text] [Related]
3. 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.
Salameh BA; Cumpstey I; Sundin A; Leffler H; Nilsson UJ
Bioorg Med Chem; 2010 Jul; 18(14):5367-78. PubMed ID: 20538469
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.
Chan YC; Lin HY; Tu Z; Kuo YH; Hsu SD; Lin CH
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382172
[TBL] [Abstract][Full Text] [Related]
5. Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor.
Masuyer G; Jabeen T; Öberg CT; Leffler H; Nilsson UJ; Acharya KR
FEBS J; 2012 Jan; 279(2):193-202. PubMed ID: 22059385
[TBL] [Abstract][Full Text] [Related]
6. Thiodigalactoside-Bovine Serum Albumin Conjugates as High-Potency Inhibitors of Galectin-3: An Outstanding Example of Multivalent Presentation of Small Molecule Inhibitors.
Zhang H; Laaf D; Elling L; Pieters RJ
Bioconjug Chem; 2018 Apr; 29(4):1266-1275. PubMed ID: 29474087
[TBL] [Abstract][Full Text] [Related]
7. A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
Rajput VK; MacKinnon A; Mandal S; Collins P; Blanchard H; Leffler H; Sethi T; Schambye H; Mukhopadhyay B; Nilsson UJ
J Med Chem; 2016 Sep; 59(17):8141-7. PubMed ID: 27500311
[TBL] [Abstract][Full Text] [Related]
8. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present).
Sethi A; Sanam S; Alvala R; Alvala M
Expert Opin Ther Pat; 2021 Aug; 31(8):709-721. PubMed ID: 33749494
[TBL] [Abstract][Full Text] [Related]
9. Linear triazole-linked pseudo oligogalactosides as scaffolds for galectin inhibitor development.
Dussouy C; Kishor C; Lambert A; Lamoureux C; Blanchard H; Grandjean C
Chem Biol Drug Des; 2020 Oct; 96(4):1123-1133. PubMed ID: 32220037
[TBL] [Abstract][Full Text] [Related]
10. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.
Hsieh TJ; Lin HY; Tu Z; Lin TC; Wu SC; Tseng YY; Liu FT; Hsu ST; Lin CH
Sci Rep; 2016 Jul; 6():29457. PubMed ID: 27416897
[TBL] [Abstract][Full Text] [Related]
11. Systematic Tuning of Fluoro-galectin-3 Interactions Provides Thiodigalactoside Derivatives with Single-Digit nM Affinity and High Selectivity.
Peterson K; Kumar R; Stenström O; Verma P; Verma PR; Håkansson M; Kahl-Knutsson B; Zetterberg F; Leffler H; Akke M; Logan DT; Nilsson UJ
J Med Chem; 2018 Feb; 61(3):1164-1175. PubMed ID: 29284090
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of new thiodigalactoside-based chemical probes to label galectin-3.
van Scherpenzeel M; Moret EE; Ballell L; Liskamp RM; Nilsson UJ; Leffler H; Pieters RJ
Chembiochem; 2009 Jul; 10(10):1724-33. PubMed ID: 19492387
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of galactose-mimicking 1H-(1,2,3-triazol-1-yl)-mannosides as selective galectin-3 and 9N inhibitors.
Tejler J; Skogman F; Leffler H; Nilsson UJ
Carbohydr Res; 2007 Sep; 342(12-13):1869-75. PubMed ID: 17407769
[TBL] [Abstract][Full Text] [Related]
14. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
[TBL] [Abstract][Full Text] [Related]
15. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
[TBL] [Abstract][Full Text] [Related]
16. Immunoprotective neo-glycoproteins: Chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3.
Heine V; Hovorková M; Vlachová M; Filipová M; Bumba L; Janoušková O; Hubálek M; Cvačka J; Petrásková L; Pelantová H; Křen V; Elling L; Bojarová P
Eur J Med Chem; 2021 Aug; 220():113500. PubMed ID: 33962190
[TBL] [Abstract][Full Text] [Related]
17. Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
Delaine T; Cumpstey I; Ingrassia L; Le Mercier M; Okechukwu P; Leffler H; Kiss R; Nilsson UJ
J Med Chem; 2008 Dec; 51(24):8109-14. PubMed ID: 19053747
[TBL] [Abstract][Full Text] [Related]
18. Targeting the CRD F-face of Human Galectin-3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative.
Miller MC; Zheng Y; Suylen D; Ippel H; Cañada FJ; Berbís MA; Jiménez-Barbero J; Tai G; Gabius HJ; Mayo KH
ChemMedChem; 2021 Feb; 16(4):713-723. PubMed ID: 33156953
[TBL] [Abstract][Full Text] [Related]
19. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Wdowiak K; Francuz T; Gallego-Colon E; Ruiz-Agamez N; Kubeczko M; Grochoła I; Wojnar J
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29320431
[TBL] [Abstract][Full Text] [Related]
20. Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitors.
Bum-Erdene K; Gagarinov IA; Collins PM; Winger M; Pearson AG; Wilson JC; Leffler H; Nilsson UJ; Grice ID; Blanchard H
Chembiochem; 2013 Jul; 14(11):1331-42. PubMed ID: 23864426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
